Lenalidomide in Relapsed and Refractory Multiple Myeloma

Abstract

Improvement in the treatment options in multiple myeloma(MM) makes the survival rate into double during recent years but most of the patient eventually relapses. At the time of relapses, the use of alternative drugs is the current practice. Lenalidomide is an immuno-modulators and it is one of the most versatile drug which is used in several Hematological disease treatment including MM. Several clinical trials have shown a better progression free survival(PFS) and overall survival(OS) with Lenalidomide based regimens. In Pollux study, the regimen with Daratuzumab with Lenalidomide and dexamethasone has shown much better OS and PFS than only Lenalidomide and Dexamethasone. But Some times patients are refractive to Lenalidomides. In that case Pomalidomide or bortezomib based regimen is used. Although Lenalidomide is one of the most promising drug to treat both first line and Relapse-refractory case of MM. Hemato oncology is a challenging topic and its correlated with personalized medicine this days. Different clinical trial are going on with different regimen. In some patient some regimen is showing good result and in some other regimen is giving good prognosis. So its always tough to tell which is the best regimen. In this article we will focus on use of Lenalidomide based regimes and we will see the median OS and median PFS of all these Lenalidomide based regimen. All through there is a good room for research on Len refractive cases and personalized treatment in multiple myeloma in both front line and relapsed and refractory cases.